<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03499353</url>
  </required_header>
  <id_info>
    <org_study_id>C3441020</org_study_id>
    <secondary_id>TALAZOPARIB NEOADJ BC</secondary_id>
    <nct_id>NCT03499353</nct_id>
  </id_info>
  <brief_title>Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer</brief_title>
  <official_title>A Phase 2, Non-randomized, Open Label, Single Arm, Multi-center Study Of Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A PHASE 2, NON RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI CENTER STUDY OF TALAZOPARIB FOR
      NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE NEGATIVE BREAST
      CANCER
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TALAZOPARIB (PARP INHIBITOR) FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS
      WITH EARLY TRIPLE NEGATIVE BREAST CANCER. THIS IS A MONOTHERAPY TREATMENT FOR 24 WKS FOLLOWED
      BY SURGERY TO EVALUATE PATHOLOGICAL COMPLETE RESPONSE.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>THIS IS AN OPEN LABEL SINGLE ARM STUDY</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Response (pCR) by Independent Central Reviewer(ICR)</measure>
    <time_frame>Following the completion of 24 weeks of Talazoparib Treatment</time_frame>
    <description>Pathological Complete Response(pCR) by Independent Central Reviewer (ICR) defined by: defined as ypT0, ypN0 (the absence of residual invasive and in situ cancer on evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pCR by Investigator</measure>
    <time_frame>Following the completion of 24 weeks of Talazoparib Treatment</time_frame>
    <description>pCR rate by investigator is defined as the number and percentage of patients achieving pCR by investigator review after talazoparib treatment for 24 weeks, followed by surgery, among all patients in the evaluable population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Cancer Burden(RCB) by Independent reviewer</measure>
    <time_frame>Following the completion of 24 weeks of Talazoparib Treatment</time_frame>
    <description>Residual cancer burden by ICR will be reported as a categorical variable with four classes (categories) RCB 0 (pCR), I (minimal RCB), II (moderate RCB), and III (extensive RCB).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pCR by independent Reviewer in Breast</measure>
    <time_frame>Following the completion of 24 weeks of Talazoparib Treatment</time_frame>
    <description>pCR rate in breast by ICR is defined as the number and percentage of patients achieving pCR in breast by independent central review after talazoparib treatment for 24 weeks, followed by surgery, among all patients in the evaluable population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>Time of Surgery up to 36 months</time_frame>
    <description>Time of surgery to first documentation of local or distant recurrence, or death or initiation of antineoplastic therapy before documentation of first relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>First Dose of Talazoparib up to 42 months</time_frame>
    <description>Time from the first dose of Talazoparib to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Upon signing Informed Consent up to 42 months</time_frame>
    <description>Type, incidence, severity (as graded by National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v4.03), seriousness and relationship of study medications to adverse events (AE) and any laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome: Deterioration of Global Health Status</measure>
    <time_frame>First dose of Talazoparib up to 9 months</time_frame>
    <description>Time to definitive deterioration of Global Health Status per EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome: Nausea and vomiting symptoms</measure>
    <time_frame>First dose of Talazoparib up to 9 months</time_frame>
    <description>Time to definitive deterioration in nausea and vomiting symptoms per EORTC QLQ C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome: global health status/QoL, functioning, and symptoms</measure>
    <time_frame>First dose of Talazoparib up to 9 months</time_frame>
    <description>Change from baseline in global health status/QoL, functioning, and symptoms per EORTC QLQ C30 and EORTC QLQ BR 23</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome- Antiemetic Log</measure>
    <time_frame>First dose of Talazoparib up to 9 months</time_frame>
    <description>Proportion of patients with deterioration, improvement and no change in nausea and vomiting symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome: Missed Menstrual Period</measure>
    <time_frame>First dose of Talazoparib up to 9 months</time_frame>
    <description>Change from baseline in proportion of patients with missed expected menstrual period per PRO CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokenetic assessment of Talazoparib</measure>
    <time_frame>week 4, week 8, week 12</time_frame>
    <description>Plasma concentration of talazoparib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Early Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TALAZOPARIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SINGLE ARM, NON-RANDOMIZED</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TALAZOPARIB</intervention_name>
    <description>Talazoparib 1mg/day</description>
    <arm_group_label>TALAZOPARIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Germline BRCA 1/2 Mutation Positive

          -  Women and men at least 18 years of age or older.

          -  Histologically confirmed invasive triple negative Breast Cancer

          -  Tumor &gt;1.5 cm.

          -  No evidence of distant metastasis

          -  Adequate bone marrow, hepatic, and renal function

          -  ECOG performance status 0 or 1

        Exclusion Criteria:

          -  Any previous antitumor therapies for the current cancer event

          -  Evidence of distant metastasis apparent prior to randomization

          -  Patients with inflammatory breast carcinoma

          -  Malignancy within the last 3 years

          -  Previous or concomitant systemic anti cancer therapies used for the treatment of
             cancer in the last 3 years.

          -  Prior treatment with a PARP inhibitor in any disease setting

          -  Concomitant use of P gp inhibitors or inducers or BCRP inhibitors

          -  Patients who are unwilling or unable to use 2 highly effective methods of
             contraception as outlined in this protocol

          -  Major surgery within 14 days prior to study entry

          -  No known history of cardiovascular disease

          -  Active clinically significant infection

          -  Clinically significant bleeding diathesis or coagulopathy

          -  Non healing wound, ulcer or bone fracture

          -  Known hypersensitivity to any of the components of talazoparib

          -  Patients with myelodysplastic syndrome/acute myeloid leukemia

          -  Patients with uncontrolled seizures.

          -  Any evidence of other disease or any concomitant medical or psychiatric problems which
             in the opinion of the Investigator would prevent completion of treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C3441020&amp;StudyName=A+Phase+2%2C+Non-randomized%2C+Open+Label%2C+Single+Arm%2C+Multi-center+Study+Of+Talazoparib+For+Neoadjuvant+Treatment+Of+Germline+Brca1%2F2+Mutation+Patients+With+Early+Triple-negative+Breast+Cancer</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2018</study_first_submitted>
  <study_first_submitted_qc>April 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant Therapy, Triple Negative Breast Cancer, BRACA Positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Talazoparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

